8th Drug Chemistry Conference, Antalya, Türkiye, 27 Şubat - 01 Mart 2020, ss.265
Breast cancer is the most frequent cancer among women, affecting approximately 2 million women
each year, and also causes the greatest number of cancer-related deaths among women. MCF-7 cell
line was derived in 1970 from an effusion of 69-year-old female patient with invasive breast ductal
carcinoma1
.
Tamoxifen is the most commonly used treatment for patients with oestrogen-receptor positive breast
cancer and the WHO lists as an essential drug for the treatment. Due to tamoxifen, approximately
more than 500,000 women have gained health today and millions more have benefited from extended
disease-free survival2
.
Combination therapy created by using two or more therapeutic molecules together is a method that
has many advantages over mono-therapy in cancer treatment. The most important of these
advantages; lower dose effectiveness, multiple strategies can be used and side effects are reduced3
.
Gambogic acid is an anticancer traditional medicine that is isolated from Garcinia hanburyi. Gambogic
acid that have been reported for its cytotoxic/anti-proliferative effects, has shown the ability to
regulating multiple signaling pathways ranging from PI3K/AKT, mTOR to inhibition of histone acetylase
transferase4,5
.
Aim of the present study is to investigate antiproliferative effect of combination of Tamoxifen -
Gambogic acid on MCF-7 human breast cancer cells by XTT method and values were calculated by
CompuSyn software. In addition, the expression levels of some genes (Bcl2, Caspase-3, caspase-9 and
Bax) were analyzed at both mRNA and protein levels using RT-qPCR and ELISA methods.